Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2022 | Long term effects of treating levodopa-induced dyskinesia with sub-anesthetic ketamine

Torsten Falk, PhD, University of Arizona, Tuscon, AZ, comments on the potential long term effects of low-dose ketamine to in patients with levodopa-induced dyskinesia. Existing data in the mental health field has yielded promising results, where patients with treatment-resistant depression do not have negative outcomes in multiple Phase II/III trials. Additional studies are required if this is true in patients with Parkinson’s disease. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved

Disclosures

Dr. Falk has a patent for the use of ketamine as a novel treatment for levodopa-induced dyskinesia associated with Parkinson’s disease, that has been licensed to PharmaTher Inc. in 2020. He also consulted for PharmaTher Inc., and received travel support.